MyoStrain® Symposium at International Cardio-Oncology Society (ICOS) Meeting in Madrid

MORRISVILLE, N.C., September 26, 2022 – Last week was an exciting week for MyoStrain®. As previously announced, days before the International Cardio-Oncology Society (ICOS) meeting in Madrid, the European Society of Cardiology (ESC) recognized the field of Cardio-Oncology by publishing the first ever guidelines for Cardio-Oncology treatment. With the protection of the heart during cancer treatment, the hope is that the guidelines will improve the health, wellbeing, and survival of cancer patients around the world. It is hoped that with more accurate testing, physicians will be able to help personalize treatment decision-making to improve cancer treatment safety.

At the 8th Symposium in Cardio-Oncology, Cardiotox2022 meeting in Madrid, there was a symposium dedicated to MyoStrain® and its advantages over traditional testing. The speakers argued that MyoStrain® should be used as the first line test for risk stratification to ensure patients are treated appropriately rapidly and efficiently. There was an ensuing discussion about why MyoStrain® was not the standard of care diagnostic and how to implement it in clinical practice. The concern discussed was the lack of availability and awareness of MyoStrain® in the marketplace. With over 350 physicians in the audience, speakers and key opinion leaders from around the globe encouraged the adoption of MyoStrain® to heighten awareness of and experience with the test.

The meeting strongly emphasized the need for risk stratification and surveillance and the role of modern cardiac imaging. "With state-of-the-art cardiac imaging, such as Fast SENC cardiac MRI (MyoStrain®), testing can detect abnormalities of left ventricular function early before symptoms, allowing clinicians to implement cardio protection and help prevent cardiac damage from toxicity caused by otherwise effective cancer treatments," said Dr. Rafael Rivero, chief medical officer of Myocardial Solutions. Dr. Rivero added, "It is not only those undergoing cancer treatment that is a problem, but also the cancer survivors with progressive cardiac disease as a result of not being cardio-protected during cancer therapies."

Moving into the treatment guidelines is a significant step in the commercial validation of MyoStrain®. It is largely the result of the body of evidence and studies performed over the last few years. We believe that adoption will be positively impacted by these events, and we look forward to potentially having the American College of Cardiology (ACC) adopt similar guidelines at their next meeting in March 2023.